MYGN Stock Recent News

Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.

Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad's breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick model, a widely used breast cancer risk assessment calculator.

VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the recently announced master collaboration agreement between the two companies.

Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators

Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1

Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.

Myriad Genetics, Inc. (NASDAQ:MYGN ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Matthew Scalo - Senior Vice President of Investor Relations Paul Diaz - President and Chief Executive Officer Mark Verratti - Chief Commercial Officer Sam Raha - Chief Operating Officer Scott Leffler - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Doug Schenkel - Wolfe Research, LLC Daniel Brennan - TD Cowen Puneet Souda - Leerink Partners LLC Andrew Cooper - Raymond James Financial, Inc. Rachel Vatnsdal - JPMorgan Chase & Co. Subbu Nambi - Guggenheim Securities, LLC Jacob Krahenbuhl - Stephens Inc. John Kim - Bank of America Operator Thank you for standing by, and welcome to Myriad Genetics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Myriad Genetics (MYGN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.21 per share a year ago.